[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100428602":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":54,"collaborators":20,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":20,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"UMC Utrecht","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neurovascular-sparing 5x7.25 Gy MRgRT","EXPERIMENTAL","MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb",[13],"Radiation: Neurovascular-sparing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Neurovascular-sparing","Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Jochem RN van der Voort van Zyp, MD PhD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Frederik R Teunissen, MD","CONTACT","+31 (0)887550474","f.r.teunissen@umcutrecht.nl",{"name":23,"role":28,"phone":20,"phoneExt":20,"email":32},"j.r.n.vandervoortvanzyp@umcutrecht.nl",[34],{"facility":35,"status":36,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University Medical Center Utrecht","RECRUITING","Utrecht","3584CX","Netherlands","NL",{"type":42,"coordinates":43},"Point",[44,45],5.12222,52.09083,{"lat":45,"lon":44},[48,49,51,53],{"name":27,"role":28,"phone":20,"phoneExt":20,"email":30},{"name":50,"role":24,"phone":20,"phoneExt":20,"email":20},"Ruud C Wortel, MD PhD",{"name":27,"role":52,"phone":20,"phoneExt":20,"email":20},"SUB_INVESTIGATOR",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Helena M Verkooijen","Prof.dr.","100428602","erectile-function-preservation-for-prostate-cancer-radiation-therapy-erect-100428602",false,"NCT04861194","EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)","EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT); a Prospective Phase II Trial","ERECT","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically proven adenocarcinoma of the prostate\n* Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low risk: T1c-T2a, Gleason score ≤6, and PSA \\\u003C10 µg\u002FL; intermediate risk: T2b-T2c or Gleason score 7 or PSA 10-20 µg\u002FL)\n* Patients with pT1a\u002Fb tumor diagnosis after transurethral resection of the prostate (TURP)\n* Domain score of 17-25 on the International Index of Erectile Function-5 (IIEF-5) questionnaire\n* Karnofsky score of 70-100\n* Written informed consent\n\nExclusion Criteria:\n\n* Use of (neo-)adjuvant androgen deprivation therapy\n* High-risk prostate cancer according to NCCN risk categories (T3a or Gleason score 8-10 or PSA \\>20 µg\u002FL)\n* Patients with \"bulky\" iT3 tumor diagnosis\n* Previous pelvic irradiation or radical prostatectomy\n* Clinical evidence of metastatic disease\n* Patients who are unable to undergo MRI\n* Patients who are incompetent to sign written informed consent","MALE","18 Years",{"count":68,"type":69},70,"ESTIMATED","INTERVENTIONAL",[72],"NA","Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.",[75,76],"Prostate Cancer","Erectile Dysfunction Following Radiation Therapy","2026-03-03",{"date":79,"type":80},"2026-03-05","ACTUAL",{"date":82,"type":80},"2021-07-14",{"date":84,"type":69},"2027-08-10",{"name":5,"class":6},1]